Logo image
Back
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
Journal article   Open access   Peer reviewed

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Izanne Roos, Sifat Sharmin, Serkan Ozakbas, Raed Alroughani, Sara Eichau, Francois Grand'Maison, Cavit Boz, Jeannette Lechner-Scott, Katherine Buzzard, Alexandre Prat, …
CNS drugs
2026
DOI: https://doi.org/10.1007/s40263-026-01287-8
PMID: 41935174
pdf
Neurological Function1.63 MBDownloadView
Open Access CC BY-NC V4.0

Abstract

Patients aged ≥ 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score ≥ 3 within the first year are at highest risk of developing aggressive MS (EDSS ≥ 6 within 10 years). Patients without these features are at lowest risk. This study aimed to evaluate whether high-efficacy disease-modifying therapy (HE-DMT) reduced the risk of relapse and disability accumulation in individuals at high risk of aggressive MS, and whether treatment benefit varied by MS severity. This observational cohort study used longitudinal data from two registries: MSBase (international) and OFSEP (France). Adults with relapse-onset MS and an EDSS score recorded within 12 months of symptom onset were included. Patients were classified into high-risk or low-risk groups for aggressive MS based on the above strata; those at intermediate risk were excluded. A pseudo-cohort framework compared periods of continuous HE-DMT (fingolimod, cladribine, monoclonal antibodies) with periods of non-HE-DMT states (on lower-efficacy DMTs or untreated) within each aggressive MS risk stratum. Marginal structural models with repeated adjustment for time-varying confounders of treatment and censoring were used to estimate counterfactual cumulative hazards of relapses and 6-month confirmed disability worsening and improvement. An interaction between MS risk stratum and treatment strategy was tested. A secondary analysis evaluated patients who received an HE-DMT during the study period. In total, 10,405 people (2021 high risk, 8384 low risk) were included. Continuous HE-DMT reduced the risk of relapse in both high-risk and low-risk groups. There was no evidence of a difference in disability outcomes between treatment approaches. There was no evidence of an interaction between aggressive MS risk and treatment effect. In stratified analyses, lowest relapse risk was observed in the low-risk group treated with HE-DMT (hazard ratio [HR] 0.75, 95% CI 0.69-0.80). Treatment with HE-DMT was associated with relapse risk comparable to that observed in the low-risk group not treated with HE-DMT (HR 0.99, 0.87-1.13). In a secondary analysis restricted to patients who receive HE-DMT during the study timeframe, treatment with HE-DMT reduced the risk of disability worsening in the high-risk group (HR 0.75, 0.58-0.99), to the level observed in the low-risk group (HR 0.80, 0.70-0.92). HE-DMTs reduced the risk of relapse in people at both high and low risk of aggressive MS, with no evidence of differential treatment benefit. In the overall population, no evidence of a difference in disability outcomes between HE-DMT-treated and HE-DMT-untreated time was observed. However, among patients ever exposed to HE-DMT, disability worsening was less common while treated with HE-DMT.

Details

Metrics

1 Record Views
Logo image